The National Health Service (NHS) is the publicly funded healthcare system in the UK. It is divided into more than 200 NHS trusts, including over 1,000 hospitals and approximately 3,000 operating rooms.

“This is a strategic win for us in the UK market and a clear signal that the NHS is accelerating the transition to the latest advancements in neuromuscular monitoring. It’s our single largest TetraGraph order received to date in Europe, serving as an excellent reference for broader expansion. As UK guidelines strongly mandate the use of quantitative monitoring, we see significant momentum ahead and are proud to support safer anesthesia care for patients across the country”, said Philip Siberg, CEO of Senzime.

The guidelines issued by the Association of Anaesthetists of Great Britain and Ireland (AAGBI) state that quantitative monitoring is essential and should be available in every operating theatre across the UK and Ireland. The guidelines further recommend using quantitative monitoring whenever neuromuscular blocking (NMB) drugs are administered, throughout all phases of anesthesia – from initiation of neuromuscular blockade until full recovery.

Senzime’s TetraGraph system is used in thousands of operating rooms at university, public, private, military and veterans’ hospitals worldwide to enhance patient safety before, during and after surgery. By accurately monitoring neuromuscular function in real time, TetraGraph supports safe timing of intubation, individualized dosing of paralytic and reversal agents, and proper timing of tracheal extubation, ensuring safe return to spontaneous breathing after surgery.